Annual report
4886.TEDINET S100OHVN
Period2021-04-01 → 2022-03-31
Filed2022-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 37
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥56.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥4.9bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥6.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥83.3bn | at 2022-03-31 | Cons. | Assets |
| Total liabilities | ¥34.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥48.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥44.5bn | at 2021-03-31 | Cons. | Net assets |
| Cash and deposits | ¥12.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥17.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥6.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥151.22 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,734.8 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 58.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.8% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 777 | at 2022-03-31 | Cons. | Number of employees |
| Revenue | ¥1.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Operating income | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥682m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥41.3bn | at 2022-03-31 | Standalone | Assets |
| Total liabilities | ¥606m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥40.7bn | at 2022-03-31 | Standalone | Net assets |
| Cash and deposits | ¥820m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥23.79 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥15 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,443.94 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 98.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.7% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 30,563,199 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Employees | 74 | at 2022-03-31 | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 24
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 48 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥5.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥5.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥73m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | ¥360m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥136m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥73m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥73m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥37.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥653m |
| Pharmaceutical Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥2.5bn |
| Pharmaceutical Businessreportable segment | employees | at 2022-03-31 | 649 pure |
| Pharmaceutical Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥50.8bn |
| Pharmaceutical Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥50.8bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2022-03-31 | ¥42.9bn |
| Pharmaceutical Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥56.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥56.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥73m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥46.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥5.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,041
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | CurrentYearDuration_jpcrp030000-asr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 5088000000 | JPY |
| Operating income | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 360000000 | JPY |
| Operating income | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 5449000000 | JPY |
| Operating income | CurrentYearDuration_ReconcilingItemsMember | -653000000 | JPY |
| Operating income | CurrentYearDuration | 4795000000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 42910000000 | JPY |
| Assets | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3048000000 | JPY |
| Assets | CurrentYearInstant_TotalOfReportableSegmentsAndOthersMember | 45959000000 | JPY |
| Assets | CurrentYearInstant_ReconcilingItemsMember | 37338000000 | JPY |
| Assets | CurrentYearInstant | 83297000000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 2546000000 | JPY |
| Depreciation segment information | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 5000000 | JPY |
| Depreciation segment information | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 2551000000 | JPY |
| Depreciation segment information | CurrentYearDuration_ReconcilingItemsMember | 136000000 | JPY |
| Depreciation segment information | CurrentYearDuration | 2687000000 | JPY |
| Impairment loss el | CurrentYearDuration_jpcrp030000-asr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 5941000000 | JPY |
| Impairment loss el | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 11000000 | JPY |
| Impairment loss el | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 5953000000 | JPY |
| Impairment loss el | CurrentYearDuration_UnallocatedAmountsAndEliminationMember | － | JPY |
| Impairment loss el | CurrentYearDuration | 5953000000 | JPY |
| Cash and deposits | CurrentYearInstant_NonConsolidatedMember | 820000000 | JPY |
| Other ca | CurrentYearInstant_NonConsolidatedMember | 134000000 | JPY |
| Current assets | CurrentYearInstant_NonConsolidatedMember | 954000000 | JPY |
| Stocks of subsidiaries and affiliates | CurrentYearInstant_NonConsolidatedMember | 40319000000 | JPY |
| Deferred tax assets | CurrentYearInstant_NonConsolidatedMember | 27000000 | JPY |
| Investments and other assets | CurrentYearInstant_NonConsolidatedMember | 40347000000 | JPY |
| Noncurrent assets | CurrentYearInstant_NonConsolidatedMember | 40347000000 | JPY |
| Assets | CurrentYearInstant_NonConsolidatedMember | 41301000000 | JPY |
| Short term loans payable | CurrentYearInstant_NonConsolidatedMember | 300000000 | JPY |
| Current portion of long term loans payable | CurrentYearInstant_NonConsolidatedMember | 48000000 | JPY |
| Accounts payable other | CurrentYearInstant_NonConsolidatedMember | 33000000 | JPY |
| Income taxes payable | CurrentYearInstant_NonConsolidatedMember | 39000000 | JPY |
| Provision for bonuses | CurrentYearInstant_NonConsolidatedMember | 60000000 | JPY |
| Other cl | CurrentYearInstant_NonConsolidatedMember | 75000000 | JPY |
| Current liabilities | CurrentYearInstant_NonConsolidatedMember | 557000000 | JPY |
| Long term loans payable | CurrentYearInstant_NonConsolidatedMember | 48000000 | JPY |
| Noncurrent liabilities | CurrentYearInstant_NonConsolidatedMember | 48000000 | JPY |
| Liabilities | CurrentYearInstant_NonConsolidatedMember | 606000000 | JPY |
| Capital stock | CurrentYearInstant_NonConsolidatedMember | 1197000000 | JPY |
| Legal capital surplus | CurrentYearInstant_NonConsolidatedMember | 844000000 | JPY |
| Other capital surplus | CurrentYearInstant_NonConsolidatedMember | 41239000000 | JPY |
| Capital surplus | CurrentYearInstant_NonConsolidatedMember | 42084000000 | JPY |
| Other retained earnings | CurrentYearInstant_NonConsolidatedMember | 747000000 | JPY |
| Retained earnings brought forward | CurrentYearInstant_NonConsolidatedMember | 747000000 | JPY |
| Retained earnings | CurrentYearInstant_NonConsolidatedMember | 747000000 | JPY |
| Treasury stock | CurrentYearInstant_NonConsolidatedMember | -3335000000 | JPY |
| Shareholders equity | CurrentYearInstant_NonConsolidatedMember | 40695000000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember | 40695000000 | JPY |
| Liabilities and net assets | CurrentYearInstant_NonConsolidatedMember | 41301000000 | JPY |
| Operating revenue1 | CurrentYearDuration_NonConsolidatedMember | 1371000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |